Skip to main content

Paul Langlie Martin, MD, PhD

Professor of Pediatrics
Chief, Division of Pediatric Blood and Marrow Transplantation
Member of the Duke Cancer Institute
Campus mail: 1400 Morrene Rd, Durham, NC 27705
Phone: (919) 668-1124
Email address: paul.martin@duke.edu

For most of my career in Pediatric Hematology/Oncology I have focused on the use of stem cell transplant for the treatment of pediatric leukemias (ALL, AML, CML and JMML) and other non-malignant blood disorders, such as thalassemia, hemaphagocytic disorders, Wiskott-Aldrich, aplastic anemia, Diamond-Blackfan Anemia, as well as inherited metabolic diseases. In addition to focusing on determining the best use of stem cell transplants for these disorders, I have also been involved in clinical research investigating the prevention and treatment of transplant related morbidity, particularly veno-occlusive disease of the liver, infections and diffuse alveolar hemorrhage. As study chair for the Children's Oncology Group protocol 9904, I was involved in the development, implementation and analysis of a large, international frontline study of childhood acute lymphoblastic leukemia. Results from this study show that a significant number of children with certain favorable cytogenetic abnormalities in their leukemic cells and who have a rapid response to their initial chemotherapy can expect to have a >95% chance of cure when treated with relatively low intensity chemotherapy.  

For most of my time at Duke I have concentrated on providing high quality care for high risk leukemia patients who require high intensity therapies, such as stem cell transplant and immunotherapy.  As a member of the Pediatric Transplant and Cellular Therapy Division I provide clinical care for these patients.  As a member of various cooperative groups and local PI for several drug trials, I have worked to provide better care and more specific therapies for the toxicities associated with stem cell transplant.  

I have also collaborated with the Pediatric Immunology Division to provide a life-saving therapy for a small group of patients with thymic dysfunction, which causes severe immunodeficiency.  Our clinical team now provides support during these patients hospital admissions for donor thymus tissue implantation.

Education and Training

  • Fellow, Pediatric Hematology/Oncology, Pediatrics, Yale University, 1989 - 1992
  • Resident, Pediatrics, Yale University, 1988 - 1989
  • Intern, Pediatrics, Yale University, 1987 - 1988
  • Ph.D., Washington University in St. Louis, 1987
  • M.D., Washington University in St. Louis, 1987

Publications

Mahadeo, Kris M., Priti Tewari, Suhag H. Parikh, Timothy A. Driscoll, Kristin Page, Paul L. Martin, Joanne Kurtzberg, and Vinod K. Prasad. “Durable engraftment and correction of hematological abnormalities in children with congenital amegakaryocytic thrombocytopenia following myeloablative umbilical cord blood transplantation.” Pediatr Transplant 19, no. 7 (November 2015): 753–57. https://doi.org/10.1111/petr.12577.

Full Text

Yasuda, Eriko, William Mackenzie, Kristen Ruhnke, Tsutomu Shimada, Robert W. Mason, Jozef Zustin, Paul L. Martin, et al. “Molecular Genetics and Metabolism Report Long-term follow-up of post hematopoietic stem cell transplantation for Hurler syndrome: clinical, biochemical, and pathological improvements.” Mol Genet Metab Rep 2 (March 2015): 65–76. https://doi.org/10.1016/j.ymgmr.2014.12.006.

Full Text

Richardson, Paul G., Nancy A. Kernan, Stephan A. Grupp, Paul L. Martin, Robert J. Soiffer, Richard Martin, Alison Hannah, and Kathleen F. Villa. “Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival.” In Biology of Blood and Marrow Transplantation, 21:S110–S110. Elsevier BV, 2015. https://doi.org/10.1016/j.bbmt.2014.11.138.

Full Text

Ciocci, Gil, Lauren Stafford, Timothy A. Driscoll, Paul L. Martin, and Joanne Kurtzberg. “Hyperthyroidism As a Complication Following Myloablative Therapy and Stem Cell Transplantation for Childhood Diseases.” In Biology of Blood and Marrow Transplantation, 21:S214–15. Elsevier BV, 2015. https://doi.org/10.1016/j.bbmt.2014.11.329.

Full Text

McFarren, Alicia, P Brian Smith, Kristin Page, Heather B. Allewelt, Suhag Parikh, Timothy A. Driscoll, Paul L. Martin, Joanne Kurtzberg, and Vinod K. Prasad. “Outcomes of Second Unrelated Donor Cord Blood Transplants (UCBT) Performed in Children with Graft Failure of Autologous Recovery Following the First UCBT.” In Biology of Blood and Marrow Transplantation, 21:S37–38. Elsevier BV, 2015. https://doi.org/10.1016/j.bbmt.2014.11.030.

Full Text

Satwani, P., Z. Jin, P. L. Martin, M. Bhatia, J. H. Garvin, D. George, S. Chaudhury, et al. “Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma.” In Leukemia, 29:448–55, 2015. https://doi.org/10.1038/leu.2014.194.

Full Text

Richardson, Paul G., Nancy A. Kernan, Stephan A. Grupp, Paul L. Martin, Robert J. Soiffer, Richard Martin, Alison L. Hannah, and Kathleen F. Villa. “Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival.” In Blood, Vol. 124. AMER SOC HEMATOLOGY, 2014.

Scholars@Duke

McLaughlin, Colleen A., Marilyn J. Hockenberry, Joanne Kurtzberg, Rémi Hueckel, Paul L. Martin, and Sharron L. Docherty. “Standardization of health care provider competencies for intrathecal access procedures.” J Pediatr Oncol Nurs 31, no. 6 (November 2014): 304–16. https://doi.org/10.1177/1043454214543019.

Full Text

Parikh, Suhag H., Adam Mendizabal, Cara L. Benjamin, Krishna V. Komanduri, Jeyaraj Antony, Aleksandra Petrovic, Gregory Hale, et al. “A novel reduced-intensity conditioning regimen for unrelated umbilical cord blood transplantation in children with nonmalignant diseases.” Biol Blood Marrow Transplant 20, no. 3 (March 2014): 326–36. https://doi.org/10.1016/j.bbmt.2013.11.021.

Full Text

Prasad, Vinod K., Adam Mendizabal, Kristin Page, Suhag Parikh, Jessica Wishnew, Timothy A. Driscoll, Paul L. Martin, and Joanne Kurtzberg. “Interplay of Recipient-Donor Matching for HLA, Race/Ethnicity and Gender on Long Term Outcomes in 365 Pediatric Recipients of Single 4/6 Matched Unrelated Cord Blood Transplantation (UCBT) after Myeloablative Therapy.” In Biology of Blood and Marrow Transplantation, 20:S87–88. Elsevier BV, 2014. https://doi.org/10.1016/j.bbmt.2013.12.111.

Full Text

Pages